Unveiling Promising PARP12 Inhibitors through Virtual Screening for Cancer Therapy
The identified inhibitors exhibit strong potential for targeting PARP12 mutants in cancer therapy. Further <i>in vitro</i> and <i>in vivo</i> studies are required to confirm their efficacy and therapeutic viability for clinical applications.
Authors
- Sara Seifeldin (ORCID: https://orcid.org/0000-0002-4450-9728)
- Khalid Alshaghdali (ORCID: https://orcid.org/0009-0000-3014-883X)
- Samra Siddiqui
- Hanan Ali Alatawi
- Mοhd Saeed (ORCID: https://orcid.org/0000-0003-3443-386X)
- Dharmendra Kumar Yadav (ORCID: https://orcid.org/0000-0003-1102-1993)
- Amal Abu Sabaa (ORCID: https://orcid.org/0000-0003-1942-3639)
- Ankit Srivastava (ORCID: https://orcid.org/0000-0003-2076-879X)
- Hatem Rabie
Institutions
- Uppsala University (SE)
- Gachon University (KR)
- University of Ha'il (SA)
- Ministry of Health (SA)
- Indian Institute of Technology Delhi (IN)
- University of Tabuk (SA)
Publication Details
- Journal
- Current Pharmaceutical Design
- Published
- 2025-04-23
- DOI
- https://doi.org/10.2174/0113816128369323250322044605
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00